

# The *TCF7L2* rs7903146 polymorphism is associated with diabetes and obesity in an elderly cohort from Brazil

Lais Bride<sup>1</sup>, Michel Naslavsky<sup>2</sup>, Guilherme Lopes Yamamoto<sup>2</sup>, Marília Scliar<sup>2</sup>, Lucia HS Pimassoni<sup>3</sup>, Paola Sossai Aguiar<sup>1</sup>, Flavia Paula<sup>1,4</sup>, Jaqueline Wang<sup>2</sup>, Yeda Duarte<sup>5,6</sup>, Maria Rita Passos-Bueno<sup>2</sup>, Mayana Zatz<sup>2</sup>, Flávia Imbroisi Valle Errera<sup>Corresp. 1, 4</sup>

<sup>1</sup> Biotechnology Graduate Program, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil

<sup>2</sup> Biosciences Institute, University of São Paulo, São Paulo, São Paulo, Brazil

<sup>3</sup> School of Science of Santa Casa de Misericórdia de Vitória, Vitória, Espírito Santo, Brazil

<sup>4</sup> Department of Biological Sciences, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil

<sup>5</sup> School of Nursing, University of São Paulo, São Paulo, São Paulo, Brazil

<sup>6</sup> School of Public Health, University of São Paulo, São Paulo, São Paulo, Brazil

Corresponding Author: Flávia Imbroisi Valle Errera  
Email address: flavia.valle@ufes.br

**Background.** Type 2 diabetes mellitus (T2DM) and obesity are complex diseases considered pandemics in the 21st century. The T allele rs7903146 in the *TCF7L2* gene is worldwide recognized as a strong GWAS signal associated with T2DM. However, the association between C allele and obesity is still poorly explored and needs to be replicated in other populations. Thus, the main objectives of this study were to evaluate the *TCF7L2* rs7903146 association with T2DM according to BMI status and to verify if this variant is related to obesity and BMI variation in a cohort of elderly Brazilians.

**Methods.** A total of 1,023 participants from an elderly census-based cohort called SABE (Saúde, Bem Estar e Envelhecimento - Health, Well-Being and Aging) were stratified by BMI status and type 2 diabetes presence. The *TCF7L2* genotypes were filtered from the Online Archive of Brazilian Mutations (ABraOM - Online Archive of Brazilian Mutations) database: a web-based public database with sequencing data of samples of the SABE's participants. Logistic regression models and interaction analysis were performed. The BMI variation ( $\Delta$ BMI) was calculated from anthropometric data collected in up to two time-points with a ten-year assessment interval.

**Results.** The association between rs7903146 T allele and T2DM was inversely proportional to the BMI status, with an increased risk in the normal-weight group (OR 3.36; 95% CI 1.46-7.74;  $P=0.004$ ). We confirmed the T allele association with risk for T2DM after adjusting for possible confounders factors (OR 2.35; 95% CI 1.28 - 4.32;  $P=0.006$ ). Interaction analysis showed that the increased risk for T2DM conferred by T allele is modified by BMI ( $P_{\text{interaction}}=0.008$ ), age ( $P_{\text{interaction}}=0.005$ ) and gender ( $P_{\text{interaction}}=0.026$ ). A T allele protective effect against obesity was observed (OR 0.71; 95% CI 0.54-0.94;  $P=0.016$ ). The C allele increased obesity risk (OR 1.40; 95% CI 1.06-1.84;  $P=0.017$ ) and the CC genotype showed a borderline association with abdominal obesity risk (OR 1.28; 95% CI 1.06-1.67;  $P=0.045$ ). The CC genotype increased the obesity risk after adjusting for possible confounders factors (OR 1.41; 95% CI 1.06 - 1.86;  $P=0.017$ ). An increase of the TT genotype in the second tertile of  $\Delta$ BMI values was observed in participants without type 2 diabetes (OR 5.13; 95% CI 1.40-18.93;  $P=0.009$ ) in the recessive genetic model. **Conclusion.** We confirmed that the rs7903146 is both associated with T2DM and obesity. The *TCF7L2* rs7903146 T allele increased T2DM risk in the normal-weight group and interacts with sex age BMI, while the C allele increased obesity risk. The TT genotype was associated with a lesser extent of BMI

variation over the ten years of the SABE study.

1 **The *TCF7L2* rs7903146 polymorphism is associated**  
2 **with diabetes and obesity in an elderly cohort from**  
3 **Brazil**

4  
5

6 Lais de Lima Bride<sup>1</sup>, Michel Satya Naslavsky<sup>2</sup>, Guilherme Lopes Yamamoto<sup>2</sup>, Marilia Oliveira  
7 Scliar<sup>2</sup>, Lúcia Helena Sagrillo Pimassoni<sup>3</sup>, Paola Sossai Aguiar<sup>1</sup>, Flávia de Paula<sup>1,4</sup>, Jaqueline Yu  
8 Ting Wang<sup>2</sup>, Yeda Aparecida Oliveira Duarte<sup>5,6</sup>, Maria Rita Passos-Bueno<sup>2</sup>, Mayana Zatz<sup>2</sup>,  
9 Flávia Imbroisi Valle Errera<sup>1,4</sup>

10

11 <sup>1</sup> Biotechnology Graduate Program, Federal University of Espírito Santo, Vitória, Espírito Santo,  
12 Brazil

13 <sup>2</sup> Human Genome and Stem Cell Research Center, Biosciences Institute, University of São  
14 Paulo, São Paulo, Brazil

15 <sup>3</sup> School of Science of Santa Casa de Misericórdia de Vitória, Vitória, Brazil

16 <sup>4</sup> Center for Human and Molecular Genetics, Department of Biological Sciences, Center for  
17 Human and Natural Sciences, Federal University of Espírito Santo, Vitória, Espírito Santo,  
18 Brazil

19 <sup>5</sup> School of Nursing, University of São Paulo, São Paulo, Brazil

20 <sup>6</sup> School of Public Health, University of São Paulo, São Paulo, Brazil

21

22 Corresponding Author:

23 Flávia Errera<sup>1,4</sup>

24 Avenida Fernando Ferrari 514 Edifício Lydia Behar sala 105, Vitória, Espírito Santo, zip code  
25 29075-910, Brazil.

26 Email address: [flavia.errera@gmail.com](mailto:flavia.errera@gmail.com)

27

28

29

30

31

32

33

34

35

36

37

38

39

40 **Abstract**

41 **Background.** Type 2 diabetes mellitus (T2DM) and obesity are complex diseases considered  
42 pandemics in the 21st century. The T allele rs7903146 in the *TCF7L2* gene is worldwide  
43 recognized as a strong GWAS signal associated with T2DM. However, the association between  
44 C allele and obesity is still poorly explored and needs to be replicated in other populations. Thus,  
45 the main objectives of this study were to evaluate the *TCF7L2* rs7903146 association with  
46 T2DM according to BMI status and to verify if this variant is related to obesity and BMI  
47 variation in a cohort of elderly Brazilians.

48

49 **Methods.** A total of 1,023 participants from an elderly census-based cohort called SABE (Saúde,  
50 Bem Estar e Envelhecimento - Health, Well-Being and Aging) were stratified by BMI status and  
51 type 2 diabetes presence. The *TCF7L2* genotypes were filtered from the Online Archive of  
52 Brazilian Mutations (ABraOM - Online Archive of Brazilian Mutations) database: a web-based  
53 public database with sequencing data of samples of the SABE's participants. Logistic regression  
54 models and interaction analysis were performed. The BMI variation ( $\Delta$ BMI) was calculated from  
55 anthropometric data collected in up to two time-points with a ten-year assessment interval.

56

57 **Results.** The association between rs7903146 T allele and T2DM was inversely proportional to  
58 the BMI status, with an increased risk in the normal-weight group (OR 3.36; 95% CI 1.46-7.74;  
59  $P=0.004$ ). We confirmed the T allele association with risk for T2DM after adjusting for possible  
60 confounders factors (OR 2.35; 95% CI 1.28 – 4.32;  $P=0.006$ ). Interaction analysis showed that  
61 the increased risk for T2DM conferred by T allele is modified by BMI ( $P_{interaction}=0.008$ ), age  
62 ( $P_{interaction}=0.005$ ) and gender ( $P_{interaction}=0.026$ ). A T allele protective effect against obesity was  
63 observed (OR 0.71; 95% CI 0.54-0.94;  $P=0.016$ ). The C allele increased obesity risk (OR 1.40;  
64 95% CI 1.06-1.84;  $P=0.017$ ) and the CC genotype showed a borderline association with  
65 abdominal obesity risk (OR 1.28; 95% CI 1.06-1.67;  $P=0.045$ ). The CC genotype increased the  
66 obesity risk after adjusting for possible confounders factors (OR 1.41; 95% CI 1.06 – 1.86;  
67  $P=0.017$ ). An increase of the TT genotype in the second tertile of  $\Delta$ BMI values was observed in  
68 participants without type 2 diabetes (OR 5.13; 95% CI 1.40-18.93;  $P=0.009$ ) in the recessive  
69 genetic model.

70

71 **Conclusion.** We confirmed that the rs7903146 is both associated with T2DM and obesity. The  
72 *TCF7L2* rs7903146 T allele increased T2DM risk in the normal-weight group and interacts with  
73 sex age BMI, while the C allele increased obesity risk. The TT genotype was associated with a  
74 lesser extent of BMI variation over the ten years of the SABE study.

75

76

77

78

79

## 80 Introduction

81 Type 2 diabetes mellitus (T2DM) and obesity are pandemic diseases interconnected by insulin  
82 mechanisms and characterized by complex interactions between environmental and genetic factors  
83 (Haupt et al., 2010; Chen et al., 2018; Grant, 2019). In this context, important T2DM genes  
84 involved in insulin production, processing, trafficking and secretion can also play a significant role  
85 in obesity development (Noordam et al., 2017; Fernández-Rhodes et al., 2018). The *TCF7L2*  
86 (10q25.2), one of these genes, encodes a transcription factor member of Wnt signaling pathway  
87 that is known to act on vital functions of  $\beta$  cells and glucose metabolizing tissues (Cropano et al.,  
88 2017).

89

90 The rs7903146 T allele in *TCF7L2* is the stronger GWAS signal for T2DM risk in different  
91 populations across the world and is associated with mechanisms related to insulin synthesis,  
92 processing, secretion and action (Grant et al., 2006; Cauchi et al., 2008b; Bouhaha et al., 2010;  
93 Zhou et al., 2014; Corella et al., 2016; Cropano et al., 2017). The genetic susceptibility for  
94 T2DM is modulated by BMI suggesting a potential relationship between the rs7903146 variant  
95 and risk for obesity, which may be related to the *TCF7L2* expression and the Wnt pathway  
96 regulation in adipose tissue (Ross et al., 2000; Grant et al., 2006; Zhou et al., 2014; Cropano et  
97 al., 2017; Chen et al., 2018).

98

99 The Wnt signaling negatively regulates adipogenesis and plays important metabolic and  
100 developmental roles in adipose tissue (Chen & Wang, 2018). Although the *TCF7L2* encodes the  
101 main effector of this signaling pathway, only a few studies investigated the association between  
102 the rs7903146 and risk for obesity (Haupt et al., 2010; Al-Daghri et al., 2014; Locke et al., 2015;  
103 Abadi et al., 2017; Muller et al., 2019). These studies reported association between rs7903146 C  
104 allele and risk for obesity. In this sense, it is important to confirm this association in other  
105 populations (Grant, 2019).

106

107 We hypothesize that rs7903146 variant is associated not only with T2DM but also with obesity.  
108 We purpose to investigate if the T2DM risk conferred by rs7903146 SNP is related to BMI status  
109 and to verify differences among the rs7903146 genotypes on BMI variation over a ten-year  
110 period. Furthermore, we performed interaction analysis of this genetic variant with BMI, age and  
111 gender.

112

113

114

115

116

117

118

## 119 **Materials & Methods**

### 120 **Study Cohort**

121 The sample belongs to elderly volunteers from a health survey called SABE (Saúde, Bem Estar e  
122 Envelhecimento - Health, Well-Being and Aging) carried out in the city of São Paulo, Brazil,  
123 under coordinated by the Pan American Health Organization. It was initiated as a multicenter  
124 health survey and well-being of older people in seven urban centers in the Caribbean and Latin  
125 America (Bridgetown, Barbados; Buenos Aires, Argentina; Havana, Cuba; Mexico City,  
126 Mexico; Montevideo, Uruguay; Santiago, Chile; and São Paulo, Brazil). Thereafter the Brazilian  
127 center has followed a longitudinal approach with a re-collection every five years, under the  
128 coordination of the Public Health School at the University of São Paulo (Lebrão & Laurenti,  
129 2005).

130

131 The Ethics in Research Committee of the School of Public Health of the University of São Paulo  
132 and the Brazilian National Committee for Ethics in Research approved the SABE study (protocol  
133 number 2015/12837/1.015.223). All participants signed consent forms following the Brazilian  
134 regulatory requirements of research with human subjects (Lebrão & Laurenti, 2005).

135 The SABE Study was approved by the Institutional Review Board of the University of São Paulo  
136 School of Public Health (CAAE: 47683115.4.0000.5421, Review: 3.600.782). A detailed  
137 description of the study population including demographic characteristics, clinical and  
138 anthropometric data, medical history and socioeconomic background is presented elsewhere  
139 (Lebrão & Laurenti, 2005). All subjects in the genomic dataset have agreed on participating in  
140 this study on written consent forms approved by CEP/CONEP (Brazilian local and national  
141 ethical committee boards).

142

### 143 **Clinical and Anthropometric Characteristics**

144 The data collection was done in participants' households by trained interviewers, using a specific  
145 standardized questionnaire (C10) proposed by the Pan American Health Organization (PAHO),  
146 translated and adapted for use in Brazil (Naslavsky et al., 2017). The T2DM was self-reported by  
147 responding to the question "has a doctor or nurse ever told you that you have diabetes or high  
148 blood sugar levels?". Blood was withdrawn and submitted to biochemical analysis and genomic  
149 analyses.

150

151 The following demographic and health variables were assessed: gender, age, fasting plasma  
152 glucose (mg/dL), glycated hemoglobin (%), total cholesterol (mg/dL), fasting triglyceride (mg /  
153 dL), LDL cholesterol (mg/dL), HDL cholesterol (mg/dL), systolic pressure (mmHg), diastolic  
154 pressure (mmHg), BMI (kg/m<sup>2</sup>), waist circumference (cm), hip circumference (cm), hip-waist  
155 ratio (cm / cm). All participants with T2DM and/or with blood glucose levels above 100 mg/dL  
156 were considered to be in a hyperglycemic state. For anthropometric evaluation, the weight was

157 measured using a portable scale (Seca, Germany), and the height with an anthropometer  
158 (Harpenden, England). Waist circumference was measured with an inelastic measurement tape  
159 placed on the midpoint between the lower margin of the last palpable riband and the top of the  
160 iliac crest. Hip circumference was measured around the widest portion of the buttocks.

161

162 The BMI was calculated from weight and height measured at baseline by dividing body weight  
163 in kg by height in meters squared. We stratified individuals in three groups according to the BMI  
164 classification from World Health Organization (WHO): normal-weight (18.5 – 24.9 kg/m<sup>2</sup>),  
165 overweight (25.0 – 29.9 kg/m<sup>2</sup>) and obesity ( $\geq 30.0$  kg/m<sup>2</sup>). Abdominal obesity was defined by  
166 the waist circumference  $> 88$  cm for women and  $> 102$  cm for men. Anthropometric data were  
167 analyzed twice over ten-years (2000 and 2010). The BMI variation ( $\Delta$ BMI) of each elderly was  
168 calculated from the difference between the BMI measured in the collection years 2010 and 2000.

169

170 After the exclusion of subjects with incomplete data, this study was performed on a multiethnic  
171 population of 1,023 elderly individuals, including men and women whose anthropometric,  
172 biochemical, and genetic information were evaluated to verify association with T2DM, obesity,  
173 and BMI variation in ten years.

174

#### 175 **Next-Generation Sequencing Data**

176 We filtered *TCF7L2* rs7903146 genotypes from the whole-genome sequencing dataset of SABE,  
177 the second phase of genomic analyses following the dataset deposited in ABraOM - *Arquivo*  
178 *Brasileiro Online de Mutações* (Online Archive of Brazilian Mutations, <http://abraom.ib.usp.br>).  
179 Quality control of genotypes and variants is described by Naslavsky et al., (2017) and by  
180 Naslavsky et al., (2020).

181

#### 182 **Statistical Analysis**

183 Data were expressed as percentages and means  $\pm$  standard deviation (SD) for continuous  
184 variables and percentages for categorical variables. The one-sample Kolmogorov-Smirnov test  
185 was used to test the normality. Differences between groups for categorical data were tested by  $\chi^2$   
186 analysis, while for continuous data Independent Samples Mann-Whitney U test and the Kruskal-  
187 Wallis test were used. Allele frequencies were determined by gene counting and departures from  
188 Hardy-Weinberg equilibrium were verified using a  $\chi^2$  test.

189

190 Allele and genotype distributions among groups were evaluated using the  $\chi^2$  test or Fisher's  
191 exact test. The level of significance adopted was  $P < 0.05$ . Logistic regression models were  
192 developed after adjusting for age and gender and were performed to assess the independent role  
193 of *TCF7L2* genotype. Interaction analysis was performed. The rs7903146 genotypic frequencies  
194 were compared among the  $\Delta$ BMI tertiles. The SPSS (version 25.0.0.0) software was used for  
195 general statistics.

196

197

198 **Results**

199 The main clinical features from 1,023 participants are depicted in Table 1. The median age of  
200 participants was 71.4 years old (59–99 years old), being 64.32% women. The three groups  
201 clustered by BMI contain 280 subjects with normal-weight, 424 with overweight and 319 with  
202 obesity participants (Table 1). These groups did not differ in systolic pressure, total cholesterol,  
203 LDL cholesterol but differed in gender ratio, age, waist circumference, hip circumference, hip-  
204 waist ratio, diastolic pressure, plasma glucose, glycated hemoglobin, fasting triglyceride, HDL  
205 cholesterol and number of subjects with T2DM and arterial hypertension (Table1).

206

207 The genotypic distributions for the rs7903146 were in Hardy-Weinberg equilibrium in all groups  
208 (All  $P>0.05$ ). These genotypic and allelic distributions of participants with and without T2DM  
209 according to BMI status are in Supplemental Table 1 (All  $P>0.05$ ). In addition, the analysis of  
210 ancestries frequency is demonstrated in Supplemental Table 2 and a significant difference in  
211 European contribution was observed among the genotypes ( $P=0.007$ ) and also between Non-  
212 T2DM and T2DM groups ( $P=0.020$ )

213

214 The TT genotype was more frequent in T2DM group ( $P=0.0001$ ). The *TCF7L2* rs7903146 T allele  
215 association with T2DM was confirmed on the recessive genetic model (OR=1.89; 95% CI: 1.21–  
216 2.95;  $P=0.004$ ), but no significant associations were detected with other phenotypes (Supplemental  
217 Table 3). Significant association signals were detected between hyperglycemic status and the T  
218 allele on dominant genetic model (OR=1.77; 95% CI: 2.61–1.20;  $P=0.004$ ) and also under the log-  
219 additive model (OR=1.56; 95% CI: 2.09–1.17;  $P=0.002$ ) (Supplemental Table 4). It was observed,  
220 conversely, a C allele protective effect against T2DM under dominant (OR=0.51; 95% CI: 0.32 –  
221 0.80;  $P=0.003$ ), additive (OR=0.50; 95% CI: 0.31 – 0.81;  $P=0.004$ ) and allelic (OR= 0.79; 95%  
222 CI: 0.64 – 0.98;  $P=0.031$ ) genetic models (Supplemental Table 5).

223

224

225 The regression analysis showed a stronger risk for T2DM on TT carriers even after adjusting for  
226 all possible confounders depicted in Table 1 (Table 2). However, the interaction analysis  
227 demonstrated that BMI modifies the association between TT genotype and T2DM risk (OR=  
228 1.02; 95% CI: 1.01 – 1.04;  $P_{interaction}=0.008$ ). This result reinforces the logistic regression  
229 analysis stratified by BMI status which showed that the risk for T2DM conferred by T allele is  
230 stronger in the normal-weight group, with the following odds ratios: (OR=3.36; 95% CI: 1.46–  
231 7.74;  $P=0.004$ ) on the recessive model and (OR=3.21; 95% CI: 1.31–7.87;  $P=0.011$ ) on the  
232 additive model (Table 3). In addition, the interaction analysis of the T allele and age  
233 demonstrated that the increased T2DM risk in TT carries is maintained and the age modified this  
234 association (OR= 1.01; 95% CI: 1.00 – 1.02;  $P_{interaction}=0.005$ ).

235

236 Association tests separated by gender showed a borderline association between TT genotype and  
237 risk for T2DM in men (OR=2.19; 95% CI: 1.05 – 4.58;  $P=0.042$ ) and a trend for association in  
238 women (OR=1.75; 95% CI: 1.00 – 3.07;  $P=0.055$ ). After grouping subjects from the normal-  
239 weight and overweight groups and excluding the obese group, we observed association both in  
240 men (OR= 2.64; 95% CI: 1.16 – 5.98;  $P= 0.020$ ) and women (OR=2.14; 95% CI: 1.08 – 4.21;  
241  $P=0.028$ ). However, in normal-weight group, we noticed a stronger association only in men  
242 (OR=5.48; 95% CI: 1.57 – 19.10;  $P=0.008$ ) and no association was found in women. Furthermore,  
243 this result is also reinforced by the interaction analysis of the TT genotype and gender on risk for  
244 T2DM (OR=1.87; 95% CI:1.08 – 3.25;  $P_{interaction}=0.026$ ).

245

246 The association between rs7903146 variant and obesity status was analyzed and the T allele  
247 conferred protection against obesity on the dominant model (OR=0.71; 95% CI: 0.54–0.94;  
248  $P=0.016$ ) (Supplemental Table 6). This result leads us to verify the association of the C allele  
249 with obesity. Our analysis revealed a CC genotype association with obesity risk on the recessive  
250 model (OR 1.40; 95% CI 1.06-1.84;  $P=0.017$ ) (Table 4). The regression analysis showed a  
251 stronger risk for obesity on CC carriers even after adjusting for all confounders possible (OR  
252 1.41; 95% CI 1.06 – 1.86;  $P=0.017$ ) (Table 5). Additionally, we observed a borderline  
253 association with abdominal obesity in subjects with CC genotype (OR=1.29; 95% CI: 1.28–1.67;  
254  $P=0.045$ ).

255

256 Analysis of BMI variation over ten years of SABE study revealed a different distribution of  
257 rs7903146 genotypes among tertiles of  $\Delta$ BMI (Supplemental Table 7). We observed an increase  
258 in the TT genotype in the  $\Delta$ BMI second tertile when compared to the first tertile in the total  
259 population on the recessive genetic model (OR 2.00; 95% CI 1.01 - 3.97;  $P= 0.044$ ) and in  
260 participants without T2DM both on the additive (OR 5.13; 95% CI 1.40-18.93;  $P= 0.009$ ) as on  
261 the recessive model (OR 5.13; 95% CI 1.43-18.37;  $P= 0.010$ ). No significant values were found  
262 among individuals with T2DM (Supplemental Table 8).

263

264

265

266

267

268

269

270

271

272

273

274

275

**276 Discussion**

277 We evaluated the *TCF7L2* rs7903146 association with T2DM and obesity. We explored whether  
278 the strength of association with T2DM depends on BMI status (normal-weight, overweight and  
279 obesity) and also investigated differences in BMI variation over ten years on C and T allele  
280 carriers. We confirmed that the T allele risk confers risk for T2DM and it is influenced by BMI  
281 status, age and gender. The TT genotype conferred a protective effect against obesity and CC  
282 genotype was associated with risk for obesity. Moreover, the TT genotype was associated with a  
283 lower BMI variation over a ten-year period in our elderly population.

284

285 According to the Allele Frequency Aggregator (ALFA) project from National Center for  
286 Biotechnology Information (NCBI) database, the worldwide frequency for the rs7903146 T  
287 allele is around 0.29 (Phan et al., 2020). In our population, the frequency of the T allele varied  
288 from 0.27 to 0.33 among the categories, except for the diabetic elderlies with normal weight  
289 which T allele frequency was around 0.40 (Supplemental Table 1). From that, we performed  
290 regression analysis adjusted for gender and age and confirmed the rs7903146 T allele risk for  
291 T2DM in the total population (Table 3).

292

293 Other Brazilian studies also reported the rs7903146 T allele association with risk for T2DM  
294 (Barra et al., 2012; Assmann et al., 2017). However, these studies did not investigate the  
295 influence of BMI on diabetes risk or addressed this issue in an elderly population. Thus, we  
296 verified an increased risk for T2DM conferred by the rs7903146 T allele in participants with  
297 lower BMI, being stronger in the normal-weight group (OR 3.36; 95% CI 1.46-7.74;  $P=0.004$ )  
298 (Table 3). Prior studies, with populations from other countries, also reported a stronger risk for  
299 T2DM in lower BMI (Cauchi et al., 2006, 2008b; Bouhaha et al., 2010; Corella et al., 2016).  
300 Cauchi et al., (2008) and Corella et al., (2016) observed in individuals without obesity odds  
301 ratios of 1.89 (95% CI: 1.67-2.14) and 2.32 (95% CI: 1.90-2.85) respectively, while Bouhaha et  
302 al., (2010) reported odds ratio similar to our (OR 3.24; 95% CI: 1.10-9.53). Perry et al., (2012)  
303 also verified a stronger risk for T2DM in individuals of normal-weight compared to obese  
304 individuals for 29 of 36 diabetes loci.

305

306 The rs7903146 T allele may have a greater impact on individuals without obesity not through  
307 obesity-induced insulin resistance but due to pancreatic dysfunction, indicating that  $\beta$ -cell  
308 impairment predicts a future T2DM in subjects with lower BMI (Cauchi et al., 2008b; Bouhaha  
309 et al., 2010). In leaner subjects, the  $\beta$ -cell compensation is lower while in people with obesity is  
310 higher (Watanabe et al., 2007). Plasmids carrying the T allele showed stronger transcriptional  
311 activity when compared to those with the C allele and pancreatic cells of T allele carriers showed  
312 impaired proinsulin processing, resulting in a high level of pro-insulin in the plasma and an  
313 increase in the proinsulin/insulin ratio (Stolerman et al., 2009). Human islets have a higher  
314 degree of open chromatin, corroborating that the T allele leads to increased expression of

315 *TCF7L2* and decreased insulin content and secretion (Zhou et al., 2014). Additionally, Zhou et  
316 al., (2014) demonstrated that in islets from CC genotype carriers, *TCF7L2* mRNA expression  
317 was negatively associated with the genes *ISLI*, *MAFA* and *NKX6.1* but not with *MAFA* and  
318 *NKX6.1* in CT/TT genotype carriers reinforcing the  $\beta$ -cell impairment in T allele risk carriers.

319  
320 He, Zhong and Cui (2014) conducted an integrated approach and observed gender difference in  
321 association signals at the gene- and pathway-level. In this study, the *TCF7L2* association was  
322 found only in male and all SNPs in this gene in the female population do not show significance.  
323 Since *TCF7L2* belongs to several enriched pathways and is widely recognized as a gene  
324 conferring risk of T2DM, the authors performed the same analysis but deleting this gene in all  
325 pathways and no significant change between pathway signals with and without gene *TCF7L2* in  
326 female group, while the strong signals in male group are almost vanished after deleting the gene,  
327 suggesting potential difference in T2DM etiology in the pathway level in each gender group;  
328 they verified that the significance of the pathways in the male group is largely dominated by  
329 gene *TCF7L2* (He, Zhong & Cui, 2014). In this sense, this finding could explain the interaction  
330 between T allele and gender on diabetes risk observed in our study.

331  
332 Our selected gene variant represents only a fraction of the potential variation of the studied gene  
333 and the mechanisms involving the *TCF7L2*, T2DM and obesity remain unknown and genetic  
334 studies with other variants are needed to better understand the *TCF7L2* role in these complex  
335 diseases. The rs12255372 variant in intron 4 of *TCF7L2* gene showed to be in strong linkage  
336 disequilibrium (LD) with rs7903146 (Pang, Smith & Humphries, 2013). Moreover, subjects  
337 homozygous for the risk-associated showed higher gene expression in pancreatic islets and were  
338 more than twice as likely to develop T2DM as non-carriers (Lyssenko et al., 2007; Pang, Smith  
339 & Humphries, 2013).

340  
341 Prior association studies reported lack of association between rs7903146 T allele and obesity  
342 status (Cauchi et al., 2008b; Stolerman et al., 2009; Bouhaha et al., 2010; Al-Safar et al., 2015).  
343 However, we verified a T allele protective effect against obesity (Supplemental Table 6) as well  
344 as the observed in more recent studies (Noordam et al., 2017; Fernández-Rhodes et al., 2018). A  
345 cross-sectional analysis conducted in middle-aged participants (mean age of  $55.9 \pm 6.0$  years)  
346 reported a T allele association with lower BMI and mean total body fat (Noordam et al., 2017).  
347 Furthermore, Fernandez-Rhodes et al. (2018) showed an association of TT genotype with  
348 decreased waist circumference and lower mean BMI at multiple time points in the life course.  
349 This protection against obesity might be due to reduced insulin production and secretion related  
350 to the rs7903146 T allele, once insulin stimulates the increased glucose uptake in adipocytes, and  
351 plays a pro-obesogenic role both from its anabolic effect on lipid accumulation and due to  
352 compensatory eating to prevent episodes of hypoglycemia (Zhou et al., 2016).

353

354 Multiple factors are related to the changes in body composition with ageing. From the fourth  
355 decade onwards, the muscle mass decline and accounts for reduced resting metabolic rates which  
356 contribute to the gradual increase in body fat in elderlies (Gallagher et al., 1998; Sayer et al.,  
357 2008). Around 75 years old, the BMI goes through a period of apparent stability, being  
358 overestimated due to the increase in fat mass and a decrease in lean mass and bone density (Ponti  
359 et al., 2020). In this sense, is not easy to differentiate lean and obese elderlies due to sarcopenic  
360 obesity and the BMI cutoff points are still controversial for this range age. Because of this, BMI  
361 classification is a limiting factor for our cohort. However, the BMI variation is an important risk  
362 predictor for elderlies and the rs7903146 T allele protective effect against obesity deserves  
363 attention because thinness is an important risk factor for health in old age and weight loss is  
364 closely related to frailty syndrome and other health complications (Aune et al., 2016; Di  
365 Angelantonio et al., 2016; Ponti et al., 2020).

366

367 Studies have been reported the clinical implications of sarcopenic obesity in subjects with T2DM  
368 (Khadra et al.; Ghoch, Calugi & Grave, 2018; Kim & Park, 2018). A recent meta-analysis  
369 observed that the presence of sarcopenic obesity increases the T2DM risk by 38% with respect to  
370 those without sarcopenic obesity (OR = 1.38, 95%CI: 1.27-1.50) (Khadra et al., 2019). The more  
371 accepted mechanism interconnecting T2DM and sarcopenic obesity involve increase in fat mass,  
372 decrease in lean mass chronic inflammation and insulin resistance, however, it is still unclear  
373 (Srikanthan, Hevener & Karlamangla, 2010). Thereby, the interaction between T allele and age  
374 on diabetes risk observed in our elderly cohort could be related to the sarcopenic obesity in older  
375 adults and the age-related decline in resting metabolic rates.

376

377 Our data suggest a differential effect of rs7903146 genotypes in BMI variation only in elderlies  
378 without T2DM. It was observed less variation in BMI during the ten years of SABE study which  
379 could be concluded from the increased number of TT genotype carriers on the second tertile of  
380  $\Delta$ BMI values (Supplemental Table 7). The same result is found in interventional studies that  
381 verified lower BMI variation in rs7903146 T allele carriers (Haupt et al., 2010; Kaminska et al.,  
382 2012; Roswall et al., 2014). Mattei et al., 2012 observed a greater loss of lean mass for CC  
383 carriers who consumed the low-fat diet compared with TT (Mattei et al., 2012). Similarly, less  
384 weight gain per year was observed in patients with the T allele compared to the C allele, after the  
385 adherence to the Mediterranean diet (Roswall et al., 2014). According to Fisher et al., (2012),  
386 the rs7903146 C allele arose during a transition from hunter-gatherer to agricultural practices  
387 (with reduced protein sources), carriers of the rs7906146 T allele were selectively adapted to  
388 maintain weight stability under low-protein conditions (Fisher et al., 2012).

389

390 Helgason et al. (2007) reported that the rs7903146 T allele probably was the ancestral allele,  
391 serving for a better subjacent mutation, and identified a haplotype with the C allele (HapA). This  
392 haplotype shows evidence of positive selection besides the association with BMI and altered  
393 concentrations of ghrelin and leptin, indicating that the selective advantage of HapA may have

394 been mediated through effects on energy metabolism (Helgason et al., 2007). Corroborating with  
395 this, the largest GWAS meta-analysis for BMI so far (~300,000 subjects), reported the C allele  
396 association with BMI (Locke et al., 2015). Although the extent of clinical variability associated  
397 with the C allele is not fully known, significant associations between the rs7903146 C allele with  
398 BMI and/or waist circumference were observed in a Saudi population (Al-Daghri et al., 2014), in  
399 European adults (Abadi et al., 2017) and American Indians (Muller et al., 2019).

400

401 The adipose tissue of CC genotype carriers expressed more transcripts containing the alternative  
402 spliced exons (13 and 13a) associated with BMI and percent body fat than T allele carriers  
403 (Kaminska et al., 2012). Further, five in seven *TCF7L2* splice forms and nine diabetes-associated  
404 genes were differentially expressed by comparing leukocyte cells of carriers of the CC and  
405 CT/TT genotypes which might reflect a significant change in gene interactions and responsible  
406 networks as glucose homeostasis, adipogenesis and other (Vaquero et al., 2012). In this sense,  
407 the *TCF7L2* alternative splicing in adipose tissue could be regulated by health, disease, weight  
408 loss and insulin resistance (Mondal et al., 2010; Kaminska et al., 2012; Vaquero et al., 2012;  
409 Zhou et al., 2014; Chen et al., 2018).

410

411 The *TCF7L2* gene plays important metabolic and developmental roles in adipose tissue, and it is  
412 largely hypothesized that the Wnt signaling is critical for obesity development (Chen & Wang,  
413 2018; Chen et al., 2018). This gene is differentially methylated in adipose tissue, exhibiting  
414 relevant epigenetic changes to the development of both diabetes as obesity (Nilsson et al., 2014).  
415 The *TCF7L2* protein inactivation is associated with increased subcutaneous adipose tissue mass,  
416 adipocyte hypertrophy and inflammation (Chen et al., 2018). Furthermore, besides alternative  
417 splicing, other regulatory changes seem to be genotype-specific and influence the *TCF7L2* role in  
418 adipose tissue. Several protein factors, including GATA3, a transcription factor that controls the  
419 preadipocyte-to-adipocyte transition, bind only to the rs7903146 C allele but not to the T allele  
420 under calorie restriction (Cauchi et al., 2008a).

421

422 The evidence above supports the CC genotype association with the risk for obesity and  
423 abdominal obesity found in our population. Thus, we speculate that the inverse effects of  
424 rs7903146 T and C alleles on risks for diabetes and obesity observed in our study might be  
425 related to the *TCF7L2* expression and its genotype-specific effects on the WNT signaling  
426 pathway in adipose tissue and others. Despite advances in knowledge regarding the production,  
427 processing, trafficking and secretion of insulin, the mechanisms interconnecting the *TCF7L2*  
428 rs7903146 variant, T2DM and obesity are not clear and more studies are required.

429

430 The main strength of this study is that the median age of our population exceeds the-age of onset  
431 of diabetes and obesity, thus minimizing a typical bias in the selection of the control group. As  
432 far as we know, this is one of the few association studies that reported an association of  
433 rs7903146 variant with BMI variation during a decade assessment interval, and with obesity

434 status in an exclusively elderly population. Dietary factors play an important role in T2DM  
435 etiology and the gene-diet interaction could influence T2DM pathogenesis (Ouhaibi-Djellouli et  
436 al., 2014; Hindy et al., 2016). Therefore, the lack of assessment of dietary as well physical  
437 activity could be a limitation of our study, however, we could detect and confirm in our  
438 population the association between T2DM and rs7903146 T allele which is worldwide  
439 recognized as the stronger GWAS signal for diabetes risk (Grant, 2019). Despite our population  
440 size, we were able to reproduce significant results following more recent studies performed on  
441 larger populations (Locke et al., 2015; Abadi et al., 2017; Fernández-Rhodes et al., 2018).

442

## 443 **Conclusions**

444 We confirmed that the rs7903146 variant is both associated with T2DM and obesity. This  
445 observation is supported by evolutive aspects and functional studies concerning the T and C  
446 allele and it contributes to expanding the knowledge about this barely explored association. In  
447 addition, we found a TT association with a lower BMI variation in elderlies over the ten years of  
448 SABE study. These findings provide a unique contribution to association studies about this  
449 polymorphism and additional studies are needed to understand the *TCF7L2* rs7903146  
450 association with obesity and with BMI variation in different age groups of populations across the  
451 world.

452

## 453 **Acknowledgments**

454 The authors acknowledge all volunteers and professional participants of the SABE survey.

455

## 456 **References**

- 457 Abadi A, Alyass A, Robiou du Pont S, Bolker B, Singh P, Mohan V, Diaz R, Engert JC, Yusuf  
458 S, Gerstein HC, Anand SS, Meyre D. 2017. Penetrance of Polygenic Obesity Susceptibility  
459 Loci across the Body Mass Index Distribution. *American Journal of Human Genetics*  
460 101:925–938. DOI: 10.1016/j.ajhg.2017.10.007.
- 461 Al-Daghri NM, Alkharfy KM, Al-Attas OS, Krishnaswamy S, Mohammed AK, Albagha OM,  
462 Alenad AM, Chrousos GP, Alokail MS. 2014. Association between type 2 diabetes  
463 mellitus-related SNP variants and obesity traits in a Saudi population. *Molecular Biology*  
464 *Reports* 41:1731–1740. DOI: 10.1007/s11033-014-3022-z.
- 465 Al-Safar H, Hassoun A, Almazrouei S, Kamal W, Afandi B, Rais N. 2015. Association of the  
466 genetic polymorphisms in transcription factor 7-like 2 and peroxisome proliferator-activated  
467 receptors-  $\gamma$  2 with type 2 diabetes mellitus and its interaction with obesity status in Emirati  
468 population. *Journal of Diabetes Research* 2015. DOI: 10.1155/2015/129695.
- 469 Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, Cairns  
470 BJ, Huxley R, Jackson CL, Joshy G, Lewington S, Manson JAE, Murphy N, Patel A V.,  
471 Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR,  
472 Collins R, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Ji Jung K,  
473 Korda RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK,  
474 Rolland B, Sacerdote C, Sattar N, Anopoulou ES, Stevens J, Thun M, Ueshima H, Yang L,  
475 Duk Yun Y, Willeit P, Banks E, Beral V, Chen Z, Gapstur SM, Gunter MJ, Hartge P, Jee

- 476 SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB. 2016. Body-  
477 mass index and all-cause mortality: individual-participant-data meta-analysis of 239  
478 prospective studies in four continents. *The Lancet* 388:776–786. DOI: 10.1016/S0140-  
479 6736(16)30175-1.
- 480 Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all  
481 cause mortality: systematic review and non-linear dose-response meta-analysis of 230  
482 cohort studies with 3.74 million deaths among 30.3 million participants. DOI:  
483 10.1136/bmj.i2156.
- 484 Bouhaha R, Choquet H, Meyre D, Kamoun HA, Ennafaa H, Baroudi T, Sassi R, Vaxillaire M,  
485 Elgaaied A, Froguel P, Cauchi S. 2010. TCF7L2 is associated with type 2 diabetes in  
486 nonobese individuals from Tunisia. *Pathologie Biologie* 58:426–429. DOI:  
487 10.1016/j.patbio.2009.01.003.
- 488 Cauchi S, Choquet H, Gutiérrez-aguilar R, Capel F, Grau K, Proença C, Dina C, Duval A,  
489 Balkau B, Marre M, Potoczna N, Langin D, Horber F, Sørensen TIA. 2008a. Effects of  
490 TCF7L2 Polymorphisms on Obesity in European Populations. *Obesity Journal* 16:476–482.  
491 DOI: 10.1038/oby.2007.77.
- 492 Cauchi S, Meyre D, Dina C, Samson C, Gallina S, Balkau B, Charpentier G, Stetsyuk V, Staels  
493 B, Frühbeck G, Froguel P. 2006. Transcription factor TCF7L2 genetic study in the French  
494 population: expression in human beta-cells and adipose tissue and strong association with  
495 type 2 diabetes. *Diabetes* 55:2903–2908. DOI: 10.2337/db06-0474.
- 496 Cauchi S, Nead KT, Choquet H, Horber F, Potoczna N, Balkau B, Marre M, Charpentier G,  
497 Froguel P, Meyre D. 2008b. The genetic susceptibility to type 2 diabetes may be modulated  
498 by obesity status : implications for association studies. *BMC Medical Genetics* 7903146:1–  
499 9. DOI: 10.1186/1471-2350-9-45.
- 500 Chen X, Ayala I, Shannon C, Fourcaudot M, Acharya NK, Jenkinson CP, Heikkinen S, Norton  
501 L. 2018. The diabetes gene and wnt pathway effector TCF7L2 regulates adipocyte  
502 development and function. *Diabetes* 67:554–568. DOI: 10.2337/db17-0318.
- 503 Chen N, Wang J. 2018. Wnt/ $\beta$ -Catenin signaling and obesity. *Frontiers in Physiology* 9:1–15.  
504 DOI: 10.3389/fphys.2018.00792.
- 505 Corella D, Coltell O, Sorlí J V., Estruch R, Quiles L, Martínez-González MÁ, Salas-Salvadó J,  
506 Castañer O, Arós F, Ortega-Calvo M, Serra-Majem L, Gómez-Gracia E, Portolés O, Fiol M,  
507 Espino JD, Basora J, Fitó M, Ros E, Ordovás JM. 2016. Polymorphism of the transcription  
508 factor 7-like 2 gene (TCF7L2) interacts with obesity on type-2 diabetes in the predimed  
509 study emphasizing the heterogeneity of genetic variants in type-2 diabetes risk prediction:  
510 Time for obesity-specific genetic risk sc. *Nutrients* 8. DOI: 10.3390/nu8120793.
- 511 Cropano C, Santoro N, Groop L, Dalla Man C, Cobelli C, Galderisi A, Kursawe R, Pierpont B,  
512 Goffredo M, Caprio S. 2017. The rs7903146 Variant in the *TCF7L2* Gene Increases the  
513 Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing  $\beta$ -Cell Function  
514 and Hepatic Insulin Sensitivity. *Diabetes Care* 40:1082–1089. DOI: 10.2337/dc17-0290.
- 515 Fernández-Rhodes L, Green Howard A, Graff M, Isasi CR, Highland HM, Young KL, Parra E,  
516 Below JE, Qi Q, Kaplan RC, Justice AE, Papanicolaou G, Laurie CC, A Grant SF, Haiman  
517 C, F Loos RJ, North KE. 2018. Complex patterns of direct and indirect association between  
518 the transcription Factor-7 like 2 gene, body mass index and type 2 diabetes diagnosis in  
519 adulthood in the Hispanic Community Health Study/ Study of Latinos. *BMC Obesity* 5:2–  
520 12. DOI: 10.1186/s40608-018-0200-x.
- 521 Fisher E, Meidtnar K, Ångquist L, Holst C, Hansen RD, Halkjær J, Masala G, Østergaard JN,

- 522 Overvad K, Palli D, Vimalaswaran KS, Tjønneland A, Van Der A DL, Wareham NJ,  
523 Sørensen TIA, Loos RJF, Boeing H. 2012. Influence of dietary protein intake and glycemic  
524 index on the association between TCF7L2 HapA and weight gain. *American Journal of*  
525 *Clinical Nutrition* 95:1468–1476. DOI: 10.3945/ajcn.111.014670.
- 526 Gallagher D, Belmonte D, Deurenberg P, Wang Z, Krasnow N, Pi-Sunyer FX, Heymsfield SB.  
527 1998. Organ-tissue mass measurement allows modeling of free and metabolically active  
528 tissue mass. *American Journal of Physiology - Endocrinology and Metabolism* 275. DOI:  
529 10.1152/ajpendo.1998.275.2.e249.
- 530 Ghoch M El, Calugi S, Grave RD. 2018. The Open Nutrition Journal Sarcopenic Obesity:  
531 Definition, Health Consequences and Clinical Management. 12:70–73. DOI:  
532 10.2174/1874288201812010070.
- 533 Grant SFA. 2019. The TCF7L2 Locus : A Genetic Window Into the Pathogenesis of Type 1 and  
534 Type 2 Diabetes. *Diabetes Care* 42:1624–1629. DOI: 10.2337/dci19-0001.
- 535 Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A,  
536 Stefansson H, Emilsson V, Helgadóttir A, Stykarsdóttir U, Magnusson KP, Walters GB,  
537 Palsdóttir E, Jonsdóttir T, Gudmundsdóttir T, Gylfason A, Saemundsdóttir J, Wilensky RL,  
538 Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G,  
539 Thorsteinsdóttir U, Gulcher JR, Kong A, Stefansson K. 2006. confers risk of type 2  
540 diabetes. 38:320–323. DOI: 10.1038/ng1732.
- 541 Haupt A, Thamer C, Heni M, Ketterer C, Machann J, Schick F, Machicao F, Stefan N, Claussen  
542 CD, Häring HU, Fritsche A, Staiger H. 2010. Gene variants of TCF7L2 influence weight  
543 loss and body composition during lifestyle intervention in a population at risk for type 2  
544 diabetes. *Diabetes* 59:747–750. DOI: 10.2337/db09-1050.
- 545 He T, Zhong PS, Cui Y. 2014. A set-based association test identifies sex-specific gene sets  
546 associated with type 2 diabetes. *Frontiers in Genetics* 5:1–8. DOI:  
547 10.3389/fgene.2014.00395.
- 548 Helgason A, Pálsson S, Thorleifsson G, Grant SFA, Emilsson V, Gunnarsdóttir S, Adeyemo A,  
549 Chen Y, Chen G, Reynisdóttir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-  
550 Johnsen K, Jorgensen T, Schäfer H, Faruque M, Doumatey A, Zhou J, Wilensky RL, Reilly  
551 MP, Rader DJ, Bagger Y, Christiansen C, Sigurdsson G, Hebebrand J, Pedersen O,  
552 Thorsteinsdóttir U, Gulcher JR, Kong A, Rotimi C, Stefansson K. 2007. Refining the  
553 impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. *Nature Genetics*  
554 39:218–225. DOI: 10.1038/ng1960.
- 555 Hindy G, Mollet IG, Rukh G, Ericson U, Orho-Melander M. 2016. Several type 2 diabetes-  
556 associated variants in genes annotated to WNT signaling interact with dietary fiber in  
557 relation to incidence of type 2 diabetes. DOI: 10.1186/s12263-016-0524-4.
- 558 Kaminska D, Kuulasmaa T, Venesmaa S, Käkälä P, Vaittinen M, Pulkkinen L, Pääkkönen M,  
559 Gylling H, Laakso M, Pihlajamäki J. 2012. Adipose Tissue TCF7L2 Splicing Is Regulated  
560 by Weight Loss and Associates With Glucose and Fatty Acid Metabolism. 61:2807–2813.  
561 DOI: 10.2337/db12-0239.
- 562 Khadra D, Itani L, Tannir H, Kreidieh D, Masri D El, Ghoch M El. Association between  
563 sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and  
564 meta-analysis ORCID number: PRISMA 2009 Checklist statement. DOI:  
565 10.4239/wjd.v10.i5.311.
- 566 Kim K, Park SM. 2018. Association of muscle mass and fat mass with insulin resistance and the  
567 prevalence of metabolic syndrome in Korean adults: a cross-sectional study OPEN.

568 *SCientiFiC REPoRtS* | 8:2703. DOI: 10.1038/s41598-018-21168-5.  
569 Lebrão ML, Laurenti R. 2005. Saúde, bem-estar e envelhecimento : o estudo SABE no  
570 Município de São Paulo. *Revista brasileira de epidemiologia = Brazilian journal of*  
571 *epidemiology* 8:127–141.

572 Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S,  
573 Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S,  
574 Kutalik Z, Luan J, Mägi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD,  
575 Smith JA, Zhao JH, Zhao W, Chen J, Fehrmann R, Hedman K, Karjalainen J, Schmidt EM,  
576 Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S,  
577 Demirkan A, Deng G, Ehret G, Feenstra B, Feitosa M, Fischer K, Goel A, Gong J, Jackson  
578 AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Leach IM,  
579 Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ,  
580 Prokopenko I, Shungin D, Stančáková A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A,  
581 Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk J V., Wang Z, Yengo L,  
582 Zhang W, Isaacs A, Albrecht E, Ärnlöv J, Arscott GM, Attwood AP, Bandinelli S, Barrett  
583 A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Blüher M, Böhringer S, Bonnycastle  
584 LL, Böttcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Chen YI, Clarke R, Daw EW, de  
585 Craen AJM, Delgado G, Dimitriou M, Doney ASF, Eklund N, Estrada K, Eury E, Folkersen  
586 L, Fraser RM, Garcia M, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall A,  
587 Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Gräßler J, Grönberg H, Groves  
588 CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward  
589 C, Heard-Costa NL, Helmer Q, Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff J,  
590 Johansson, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W,  
591 Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindström J, Lo KS,  
592 Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL,  
593 McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken  
594 MA, Mulas A, Müller G, Müller-Nurasyid M, Musk AW, Nagaraja R, Nöthen MM, Nolte  
595 IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson N, Rose LM,  
596 Sanna S, Schernagl H, Scholtens S, Schumacher F, Scott WR, Seufferlein T, Shi J, Smith A  
597 V., Smolonska J, Stanton A V., Steinthorsdottir V, Stirrups K, Stringham HM, Sundström J,  
598 Swertz MA, Swift AJ, Syvänen AC, Tan ST, Tayo B, Thorand B, Thorleifsson G, Tyrer J,  
599 Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL,  
600 Warren HR, Waterworth DM, Weedon MN, Wilkens L, Willenborg C, Wilsgaard T,  
601 Wojczynski MK, Wong A, Wright AF, Zhang Q, Brennan EP, Choi M, Dastani Z, Drong  
602 AW, Eriksson P, Franco-Cereceda A, Gådin JR, Gharavi AG, Goddard ME, Handsaker RE,  
603 Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton  
604 RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito  
605 JM, Nicholson G, Nyholt DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM,  
606 Sandholm N, Scott RA, Stolk L, Takahashi A, Van't Hooft FM, Vinkhuyzen AAE, Westra  
607 HJ, Zheng W, Zondervan KT, Heath AC, Arveiler D, Bakker SJ, Beilby JP, Bergman RN,  
608 Blangero J, Bovet P, Campbell H, Caulfield M, Cesana G, Chakravarti A, Chasman D,  
609 Chines PS, Collins FS, Crawford D, Cupples L, Cusi D, Danesh J, de Faire U, Den Ruijter  
610 HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E,  
611 Ferrières J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman P V.,  
612 Gieger C, Gottesman O, Gudnason V, Gyllensten UB, Hall AS, Harris TB, Hattersley AT,  
613 Hicks AA, Hindorff L, Hingorani A, Hofman A, Homuth G, Hovingh G, Humphries SE,

614 Hunt SC, Hyppönen E, Illig T, Jacobs KB, Jarvelin MR, Jöckel KH, Johansen B, Jousilahti  
615 P, Jukema J, Jula A, Kaprio J, Kastelein JJ, Keinanen-Kiukaanniemi SM, Kiemenev LA,  
616 Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka T,  
617 Langenberg C, Marchand LL, Lehtimäki T, Lyssenko V, Männistö S, Marette A, Matise T,  
618 McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M,  
619 Ohlsson C, Oldehinkel AJ, Ong KK, Madden PAF, Pasterkamp G, Peden JF, Peters A,  
620 Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari O, Rankinen T, Rao DC, Rice TK,  
621 Ridker P, Rioux JD, Ritchie M, Rudan I, Salomaa V, Samani N, Saramies J, Sarzynski MA,  
622 Schunkert H, Schwarz PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tönjes  
623 A, Trégouët DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Völker U, Waeber G,  
624 Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes  
625 TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C,  
626 Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PIW, Dedoussis G V., Ferrucci  
627 L, Franks PW, Froguel P, Groop L, Haiman C, Hamsten A, Hui J, Hunter DJ, Hveem K,  
628 Kaplan RC, Kivimäki M, Kuh D, Laakso M, Liu Y, Martin NG, März W, Melbye M,  
629 Metspalu A, Moebus S, Munroe P, Njølstad I, Oostra BA, Palmer CN, Pedersen NL, Perola  
630 M, Pérusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE,  
631 Saleheen D, Sattar N, Schadt E, Schlessinger D, Slagboom PE, Snieder H, Spector TD,  
632 Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst  
633 P, Walker MC, Wallaschofski H, Wareham N, Watkins H, Weir DR, Wichmann H, Wilson  
634 JF, Zanen P, Borecki I, Deloukas P, Fox CS, Heid IM, O'connell JR, Strachan DP,  
635 Stefansson K, Van Duijn C, Abecasis G, Franke L, Frayling TM, McCarthy MI, Visscher  
636 PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso  
637 I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK, Thompson JR, Goldstein  
638 BA, König IR, Cazier JB, Grundberg E, Havulinna AS, Ho WK, Hopewell JC, Eriksson N,  
639 Lundmark P, Lyytikäinen LP, Rafelt S, Tikkanen E, Van Zuydam N, Voight BF, Ziegler A,  
640 Altshuler D, Balmforth AJ, Braund PS, Burgdorf C, Claudi-Boehm S, Cox D, Do R, Doney  
641 AS, El Mokhtari N, Fontanillas P, Hager J, Han BG, Hunt SE, Kang HM, Kessler T,  
642 Knowles JW, Kolovou G, Langford C, Lokki ML, Lundmark A, Meisinger C, Melander O,  
643 Maouche S, Nikus K, Rasheed A, Rosinger S, Rubin D, Rumpf MP, Schäfer A,  
644 Sivananthan M, Song C, Stewart AF, Thorgeirsson G, van der Schoot CE, Wagner PJ,  
645 Wells GA, Wild PS, Tsun-Po Y, Basart H, Brambilla P, Cambien F, Cupples AL, Dehghan  
646 A, Diemert P, Epstein SE, Evans A, Ferrario MM, Gauguier D, Hazen SL, Holm H,  
647 Iribarren C, Jang Y, Kähönen M, Kee F, Kim HS, Klopp N, Kuulasmaa K, Laaksonen R,  
648 Ouwehand W, Parish S, Park JE, Rader DJ, Shah S, Stark K, Wallentin L, Zimmermann  
649 ME, Nieminen MS, Sandhu MS, Pastinen T, Zalloua PA, Siegbahn A, Schreiber S, Ripatti  
650 S, Blankenberg SS, O'donnell C, Reilly MP, Collins R, Roberts R, Pattaro C, Köttgen A,  
651 Garnaas M, Böger CA, Fuchsberger C, Olden M, Chen MH, Tin A, Taliun D, Li M, Gao X,  
652 Yang Q, Hundertmark C, Foster MC, O'seaghdha CM, Glazer N, Liu CT, Struchalin M, Li  
653 G, Johnson AD, Gierman HJ, Hwang SJ, Atkinson EJ, Lohman K, Cornelis MC, Chouraki  
654 V, Holliday EG, Sorice R, Deshmukh H, Ulivi S, Chu AY, Murgia F, Imboden M, Kollerits  
655 B, Pistis G, Launer L, Aspelund T, Eiriksdottir G, Mitchell BD, Schmidt H, Cavalieri M,  
656 Rao M, Hu FB, de Andrade M, Turner ST, Ding J, Andrews JS, Freedman BI, Döring A,  
657 Kolcic I, Zemunik T, Boban M, Minelli C, Wheeler HE, Igl W, Zaboli G, Wild SH,  
658 Ellinghaus D, Nöthlings U, Jacobs G, Biffar R, Endlich K, Ernst F, Kroemer HK, Nauck M,  
659 Stracke S, Völzke H, Aulchenko YS, Polasek O, Hastie N, Vitart V, Helmer C, Wang JJ,

660 Ruggiero D, Bergmann S, Viikari J, Nikopensus T, Province M, Ketkar S, Colhoun H,  
661 Doney A, Robino A, Giulianini F, Krämer BK, Portas L, Buckley BM, Adam M, Thun GA,  
662 Paulweber B, Haun M, Sala C, Metzger M, Mitchell P, Ciullo M, Kim SK, Vollenweider P,  
663 Palmer C, Gasparini P, Pirastu M, Probst-Hensch NM, Kronenberg F, Toniolo D, Coresh J,  
664 Schmidt R, Siscovick D, Kardina SL, Curhan GC, Franke A, Parsa A, Goessling W, Kao W,  
665 de Boer IH, Peralta CA, Akylbekova E, Kramer H, Arking DE, Franceschini N, Egan J,  
666 Hernandez D, Townsend RR, Lumley T, Psaty B, Kestenbaum B, Haritunians T, Mooser V,  
667 Florez JC, Meigs JB, Lu X, Leak TS, Aasarød K, Skorpen F, Baumert J, Devuyst O,  
668 Mychaleckyj JC, Kedenko L, Coassin S, Hallan S, Navis G, Shlipak MG, Bull SB, Paterson  
669 AD, Rotter JI, Dreisbach AW, Anderson CA, Guo Q, Henders A, Lambert A, Lee SH, Kraft  
670 P, Kennedy SH, Macgregor S, Missmer SA, Painter JN, Roseman F, Treloar SA, Wallace L,  
671 Forsblom C, Isakova T, McKay GJ, Williams WW, Sadlier DM, Mäkinen VP, Swan EJ,  
672 Boright AP, Ahlqvist E, Keller BJ, Huang H, Ahola A, Fagerholm E, Gordin D, Harjutsalo  
673 V, He B, Heikkilä O, Hietala K, Kytö J, Lahermo P, Lehto M, Österholm AM, Parkkonen  
674 M, Pitkaniemi J, Rosengård-Bärlund M, Saraheimo M, Sarti C, Söderlund J, Soro-Paavonen  
675 A, Syreeni A, Thorn LM, Tikkanen H, Tolonen N, Tryggvason K, Wadén J, Gill G V., Prior  
676 S, Guiducci C, Mirel D, Taylor A, Hosseini M, Parving HH, Rossing P, Tarnow L,  
677 Ladenvall C, Alhenc-Gelas F, Lefebvre P, Rigalleau V, Roussel R, Tregouet DA, Maestroni  
678 A, Maestroni S, Falhammar H, Gu T, Möllsten A, Cimponeriu D, Mihai I, Mota M, Mota E,  
679 Serafinceanu C, Stavarachi M, Hanson RL, Nelson RG, Kretzler M, Panduru NM, Gu HF,  
680 Brismar K, Zerbini G, Hadjadj S, Marre M, Lajer M, Waggott D, Savage DA, Bain SC,  
681 Martin F, Godson C, Groop PH, Maxwell AP, Sengupta S, Peloso GM, Ganna A, Mora S,  
682 Chang HY, Den Hertog HM, Donnelly LA, Freitag DF, Gurdasani D, Heikkilä K, Johnson  
683 T, Kaakinen M, Kettunen J, Li X, Montasser ME, Petersen AK, Saxena R, Service SK,  
684 Sidore C, Surakka I, Teslovich TM, Van den Herik EG, Volcik KA, Wu Y, Asiki G, Been  
685 LF, Burnett MS, Doring A, Elliott P, Eyjolfsson GI, Goodarzi MO, Gravito ML,  
686 Hartikainen AL, Hung YJ, Jones MR, Kaleebu P, Khaw KT, Kim E, Komulainen P,  
687 Lehtimäki T, Lin SY, Lindstrom J, Muller G, Narisu N, Nieminen T V., Nsubuga RN,  
688 Olafsson I, Palotie A, Papamarkou T, Pomilla C, Pouta A, Ruokonen A, Seeley J, Silander  
689 K, Tired L, van Pelt L, Wainwright N, Wijmenga C, Young EH, Bennett F, Boomsma DI,  
690 Burnier M, Chen YD, Feranil AB, Ferrieres J, Freimer NB, Hsiung CA, Kesäniemi A,  
691 Koudstaal PJ, Krauss RM, Kyvik KO, Meneton P, Moilanen L, Sanghera DK, Sheu WH,  
692 Whitfield JB, Wolffenbuttel BH, Ordovas JM, Rich SS, Johnson A, Johnson L, Larson MG,  
693 Levy D, Newton-Cheh C, O'reilly PF, Palmas W, Rice K, Smith A, Snider H, Tobin M,  
694 Verwoert G, Rice KM, Verwoert GC, Pihur V, Heath S, Söber S, Arora P, Zhang F, Lucas  
695 G, Milaneschi Y, Parker AN, Fava C, Fox ER, Go MJ, Sjögren M, Vinay D, Alexander M,  
696 Tabara Y, Shaw-Hawkins S, Whincup PH, Shi G, Seielstad M, Sim X, Nguyen KD,  
697 Matullo G, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R,  
698 Dahgam S, Palmen J, Kuznetsova T, Uiterwaal CS, Adeyemo A, Ludwig B, Tomaszewski  
699 M, Tzoulaki I, Palmer ND, Chang YP, Steinle NI, Grobbee DE, Morrison AC, Najjar S,  
700 Hadley D, Brown MJ, Connell JM, Day IN, Lawlor DA, Lawrence RW, Ongen H, Li Y,  
701 Young JH, Bis JC, Bolton JA, Chaturvedi N, Islam M, Jafar TH, Kulkarni SR, Howard P,  
702 Guarrera S, Ricceri F, Emilsson V, Plump AS, Weder AB, Sun Y V., Scott LJ, Peltonen L,  
703 Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Artigas MS, Dong Y, Wang X,  
704 Zhu H, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Doumatey A, Shriner D, Veldre  
705 G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle

706 DS, Corsi AM, Singleton A, Hilton G, Salako T, Iwai N, Kita Y, Ogihara T, Ohkubo T,  
707 Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Cho YS, Kim HL,  
708 Scott J, Sehmi JS, Hedblad B, Nilsson P, Smith GD, Raffel LJ, Yao J, Schwartz SM, Ikram  
709 M, W L, Mosley TH, Seshadri S, Shrine NR, Wain L V., Zitting P, Cooper JA, van Gilst  
710 WH, Janipalli CS, Mani K, Yajnik CS, Mattace-Raso FU, Lakatta EG, Orru M, Scuteri A,  
711 Ala-Korpela M, Kangas AJ, Soininen P, Tukiainen T, Würtz P, Ong RT, Dörr M, Galan P,  
712 Hercberg S, Lathrop M, Zelenika D, Zhai G, Meschia JF, Sharma P, Terzic J, Kumar M,  
713 Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes F, Charchar FJ, Guo X,  
714 Rotimi C, Bots ML, Brand E, Talmud PJ, Nyberg F, Laan M, Palmer LJ, van der Schouw  
715 YT, Casas JP, Vineis P, Ganesh SK, Wong TY, Tai ES, Morris RW, Marmot MG, Miki T,  
716 Chandak GR, Zhu X, Elosua R, Soranzo N, Sijbrands EJ, Uda M, Vasani RS, Järvelin MR,  
717 Alizadeh BZ, de Boer RA, Boezen HM, Hillege HL, van der Klauw MM, Ormel J,  
718 Rosmalen JG, Slaets JP, Lagou V, Welch RP, Wheeler E, Rehnberg E, Rasmussen-Torvik  
719 LJ, Lecoeur C, Johnson PC, Sennblad B, Salo P, Timpson NJ, Evans DM, St Pourcain B,  
720 Bielak LF, Horikoshi M, Navarro P, Raychaudhuri S, Chen H, Rybin D, Willems SM, Song  
721 K, An P, Marullo L, Jansen H, Pankow J, Edkins S, Varga T V., Oksa H, Antonella M,  
722 Kong A, Herder C, Antti J, Small KS, Miljkovic I, Atalay M, Kiess W, Smit JH, Campbell  
723 S, Fowkes GR, Rathmann W, Maerz W, Watanabe RM, de Geus EJ, Penninx BW, Toenjes  
724 A, Peyser PA, Körner A, Dupuis J, Cucca F, Balkau B, Bouatia-Naji N, Purcell S,  
725 Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Morgan T, Spertus JA, Stoll  
726 M, Girelli D, McKeown PP, Patterson CC, Merlini PA, Berzuini C, Bernardinelli L,  
727 Peyvandi F, Tubaro M, Celli P, Fève R, Marziliano N, Casari G, Galli M, Ribichini F,  
728 Rossi M, Bernardi F, Zonin P, Piazza A, Yee J, Friedlander Y, Marrugat J, Subirana I, Sala  
729 J, Ramos R, Williams G, Nathan DM, Macrae CA, Berglund G, Asselta R, Duga S,  
730 Spreafico M, Daly MJ, Nemes J, Korn JM, Surti A, Gianniny L, Parkin M, Burt N,  
731 Gabriel SB, Wright BJ, Ball SG, Schunkert I, Linsel-Nitschke P, Lieb W, Fischer M,  
732 Grosshennig A, Preuss M, Scholz M, Chen Z, Wilensky R, Matthai W, Qasim A,  
733 Hakonarson HH, Devaney J, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R,  
734 Knouff CW, Scheffold T, Berger K, Hogue A, Martinelli N, Olivieri O, Corrocher R, Hólm  
735 H, Xie C, Ahmadi KR, Ainali C, Bataille V, Bell JT, Buil A, Dermitzakis ET, Dimas AS,  
736 Durbin R, Glass D, Hassanali N, Ingle C, Knowles D, Krestyaninova M, Lowe CE, Meduri  
737 E, Di Meglio P, Montgomery SB, Nestle FO, Nica AC, Nisbet J, O'rahilly S, Parts L, Potter  
738 S, Sekowska M, Shin SY, Surdulescu G, Travers ME, Tsaprouni L, Tsoka S, Wilk A, Yang  
739 TP, Higashio J, Williams R, Nato A, Ambite JL, Deelman E, Manolio T, Heiss G, Taylor K,  
740 Avery C, Graff M, Lin D, Quibrera M, Cochran B, Kao L, Umans J, Cole S, Maccluer J,  
741 Person S, Gross M, Fornage M, Durda P, Jenny N, Patsy B, Arnold AM, Buzkova P, Haines  
742 J, Murdock D, Glenn K, Brown-Gentry K, Thornton-Wells T, Dumitrescu L, Bush WS,  
743 Mitchell SL, Goodloe R, Wilson S, Boston J, Malinowski J, Restrepo N, Oetjens M, Fowke  
744 J, Spencer K, Pendergrass S, Le Marchand L, Park L, Tiirikainen M, Kolonel L, Cheng I,  
745 Wang H, Shohet R, Stram D, Henderson B, Monroe K, Anderson G, Carlson C, Prentice R,  
746 Lacroix A, Wu C, Carty C, Rosse S, Young A, Kocarnik J, Lin Y, Jackson R, Duggan D,  
747 Kuller L, He C, Sulem P, Barbalic M, Broer L, Byrne EM, Gudbjartsson DF, McArdle PF,  
748 Porcu E, van Wingerden S, Zhuang W V., Lauc LB, Broekmans FJ, Burri A, Chen C, Corre  
749 T, Coviello AD, D'adamo P, Davies G, Deary IJ, Ebrahim S, Fauser BC, Ferrelly L, Folsom  
750 AR, Hankinson SE, Hass M, Janssens AC, Karasik D, Keyzer J, Kiel DP, Lahti J, Lai S,  
751 Laisk T, Laven JS, Liu J, Lopez LM, Louwers Y V., Marongiu M, Klaric IM, Masciullo C,

- 752 Melzer D, Newman AB, Paré G, Peeters PH, Pop VJ, Räikkönen K, Salumets A, Stacey  
753 SN, Starr JM, Stathopoulou MG, Stykarsdottir U, Tenesa A, Tryggvadottir L, Tsui K, van  
754 Dam RM, van Gils CH, van Nierop P, Vink JM, Voorhuis M, Widen E, Wijnands-Van Gent  
755 CJ, Yerges-Armstrong LM, Zgaga L, Zygmont M, Buring JE, Crisponi L, Demerath EW,  
756 Streeten EA, Murray A, Visser JA, Lunetta KL, Elks CE, Cousminer DL, Koller DL, Lin P,  
757 Smith EN, Warrington NM, Alavere H, Berenson GS, Blackburn H, Busonero F, Chen W,  
758 Couper D, Easton DF, Eriksson J, Foroud T, Kilpeläinen TO, Li S, Murray SS, Ness AR,  
759 Northstone K, Peacock M, Pennell CE, Pharoah P, Rafnar T, Rice JP, Ring SM, Schork NJ,  
760 Segrè A V., Sovio U, Srinivasan SR, Tammesoo ML, van Meurs JB, Young L, Bierut LJ,  
761 Econs MJ. 2015. Genetic studies of body mass index yield new insights for obesity biology.  
762 *Nature* 518:197–206. DOI: 10.1038/nature14177.
- 763 Lyssenko V, Lupi R, Marchetti P, Guerra S Del, Orho-melander M, Almgren P, Sjögren M, Ling  
764 C, Eriksson K, Lethagen Å, Mancarella R, Berglund G, Tuomi T, Nilsson P, Prato S Del,  
765 Groop L. 2007. Mechanisms by which common variants in the TCF7L2 gene increase risk  
766 of type 2 diabetes. 117:2155–2163. DOI: 10.1172/JCI30706DS1.
- 767 Mattei J, Qi Q, Hu FB, Sacks FM, Qi L. 2012. TCF7L2 genetic variants modulate the effect of  
768 dietary fat intake on changes in body composition during a weight-loss intervention.  
769 *American Journal of Clinical Nutrition* 96:1129–1136. DOI: 10.3945/ajcn.112.038125.
- 770 Mondal AK, Das SK, Baldini G, Chu WS, Sharma NK, Hackney OG, Zhao J, Grant SFA, Elbein  
771 SC. 2010. Genotype and tissue-specific effects on alternative splicing of the transcription  
772 factor 7-like 2 gene in humans. *Journal of Clinical Endocrinology and Metabolism*  
773 95:1450–1457. DOI: 10.1210/jc.2009-2064.
- 774 Muller YL, Hanson RL, Piaggi P, Chen P, Wiessner G, Okani C, Skelton G, Kobes S, Hsueh W,  
775 Knowler WC, Bogardus C, Baier LJ. 2019. Assessing the Role of 98 Established Loci for  
776 Body Mass Index in American Indians. *Obesity* 27:845–854. DOI:  
777 10.1002/oby.22433.Assessing.
- 778 Naslavsky MS, Scliar MO, Yamamoto GL, Wang JYT, Zverinova S, Karp T, Nunes K, Ceroni  
779 JRM, de Carvalho DL, da Silva Simões CE, Bozoklian D, Nonaka R, Silva N dos SB, da  
780 Silva Souza A, de Souza Andrade H, Passos MRS, Castro CFB, Mendes-Junior CT,  
781 Mercuri RL V, Miller TLA, Buzzo JL, Rego FO, Araújo NM, Magalhães WCS, Célia  
782 Mingroni-Netto R, Borda V, Guio H, Barreto ML, Lima-Costa MF, Horta BL, Tarazona-  
783 Santos E, Meyer D, Galante PAF, Guryev V, Castelli EC, Duarte YAO, Passos-Bueno MR,  
784 Zatz M. 2020. Whole-genome sequencing of 1,171 elderly admixed individuals from the  
785 largest Latin American metropolis (São Paulo, Brazil). *bioRxiv*:2020.09.15.298026. DOI:  
786 10.1101/2020.09.15.298026.
- 787 Naslavsky MS, Yamamoto GL, de Almeida TF, Ezquina SAM, Sunaga DY, Pho N, Bozoklian  
788 D, Sandberg TOM, Brito LA, Lazar M, Bernardo DV, Amaro E, Duarte YAO, Lebrão ML,  
789 Passos-Bueno MR, Zatz M. 2017. Exomic variants of an elderly cohort of Brazilians in the  
790 ABraOM database. *Human Mutation* 38:751–763. DOI: 10.1002/humu.23220.
- 791 Nilsson E, Jansson PA, Perfilyev A, Volkov P, Pedersen M, Svensson MK, Poulsen P, Ribel-  
792 Madsen R, Pedersen NL, Almgren P, Fadista J, Rönn T, Pedersen BK, Scheele C, Vaag A,  
793 Ling C. 2014. Altered DNA methylation and differential expression of genes influencing  
794 metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. *Diabetes*  
795 63:2962–2976. DOI: 10.2337/db13-1459.
- 796 Noordam R, Zwetsloot CPA, de Mutsert R, Mook-Kanamori DO, Lamb HJ, de Roos A, de  
797 Koning EJP, Rosendaal FR, Willems van Dijk K, van Heemst D. 2017. Interrelationship of

- 798 the rs7903146 TCF7L2 gene variant with measures of glucose metabolism and adiposity:  
799 The NEO study. *Nutrition, Metabolism and Cardiovascular Diseases* 31:150–157. DOI:  
800 10.1016/j.numecd.2017.10.012.
- 801 Ouhaibi-Djellouli H, Mediene-Benchekor S, Lardjam-Hetraf SA, Hamani-Medjaoui I, Meroufel  
802 DN, Boulenouar H, Hermant X, Saidi-Mehtar N, Amouyel P, Houti L, Goumidi L,  
803 Meirhaeghe A. 2014. *The TCF7L2 rs7903146 polymorphism, dietary intakes and type 2*  
804 *diabetes risk in an Algerian population*. DOI: 10.1186/s12863-014-0134-3.
- 805 Pang DX, Smith AJP, Humphries SE. 2013. Functional analysis of TCF7L2 genetic variants  
806 associated with type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*  
807 23:550–556. DOI: 10.1016/j.numecd.2011.12.012.
- 808 Perry JRB, Voight BF, Yengo L, Amin N, Dupuis J, Ganser M, Grallert H, Navarro P, Li M, Qi  
809 L, Steinthorsdottir V, Scott RA, Almgren P, Arking DE, Aulchenko Y, Balkau B,  
810 Benediktsson R, Bergman RN, Boerwinkle E, Bonnycastle L, Burt NP, Campbell H,  
811 Charpentier G, Collins FS, Gieger C, Green T, Hadjadj S, Hattersley AT, Herder C,  
812 Hofman A, Johnson AD, Kottgen A, Kraft P, Labruno Y, Langenberg C, Manning AK,  
813 Mohlke KL, Morris AP, Oostra B, Pankow J, Petersen AK, Pramstaller PP, Prokopenko I,  
814 Rathmann W, Rayner W, Roden M, Rudan I, Rybin D, Scott LJ, Sigurdsson G, Sladek R,  
815 Thorleifsson G, Thorsteinsdottir U, Tuomilehto J, Uitterlinden AG, Vivequin S, Weedon  
816 MN, Wright AF, Hu FB, Illig T, Kao L, Meigs JB, Wilson JF, Stefansson K, van Duijn C,  
817 Altschuler D, Morris AD, Boehnke M, McCarthy MI, Froguel P, Palmer CNA, Wareham  
818 NJ, Groop L, Frayling TM, Cauchi S. 2012. Stratifying type 2 diabetes cases by BMI  
819 identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared  
820 to obese cases. *PLoS Genetics* 8. DOI: 10.1371/journal.pgen.1002741.
- 821 L. Phan, Y. Jin, H. Zhang, W. Qiang, E. Shekhtman, D. Shao, D. Revoe, R. Villamarin, E.  
822 Ivanchenko, M. Kimura, Z. Y. Wang, L. Hao, N. Sharopova, M. Bihan, A. Sturcke, M. Lee,  
823 N. Popova, W. Wu, C. Bastiani, M. Ward, J. B. Holmes, V. Lyoshin, K. Kaur, E. Moyer, M.  
824 Feolo, and B. L. Kattman. "ALFA: Allele Frequency Aggregator." *National Center for*  
825 *Biotechnology Information, U.S. National Library of Medicine, 10 Mar. 2020,*  
826 *www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/*
- 827 Ponti F, Santoro A, Mercatelli D, Gasperini C, Conte M, Martucci M, Sangiorgi L, Franceschi C,  
828 Bazzocchi A. 2020. Aging and Imaging Assessment of Body Composition: From Fat to  
829 Facts. *Frontiers in Endocrinology* 10. DOI: 10.3389/fendo.2019.00861.
- 830 Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. 2000.  
831 Inhibition of adipogenesis by Wnt signaling. *Science* 289:950–953. DOI:  
832 10.1126/science.289.5481.950.
- 833 Roswall N, Ångquist L, Ahluwalia TS, Romaguera D, Larsen SC, Østergaard JN, Halkjær J,  
834 Vimalaswaran KS, Wareham NJ, Bendinelli B, Palli D, Boer JMA, Van Der A DL, Boeing  
835 H, Loos RJF, Sørensen TIA, Tjønneland A. 2014. Association between Mediterranean and  
836 Nordic diet scores and changes in weight and waist circumference: Influence of FTO and  
837 TCF7L2 loci. *American Journal of Clinical Nutrition* 100:1188–1197. DOI:  
838 10.3945/ajcn.114.089706.
- 839 Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C. 2008. The developmental origins  
840 of sarcopenia. *Journal of Nutrition, Health and Aging* 12:427. DOI: 10.1007/BF02982703.
- 841 Srikanthan P, Hevener AL, Karlamangla AS. 2010. Sarcopenia Exacerbates Obesity-Associated  
842 Insulin Resistance and Dysglycemia: Findings from the National Health and Nutrition  
843 Examination Survey III. *PLoS ONE* 5:e10805. DOI: 10.1371/journal.pone.0010805.
- 844 Stolerman ES, Manning AK, McAteer JB, Fox CS, Dupuis J, Meigs JB, Florez JC. 2009.

845 TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits  
846 in the Framingham Heart Study. *Diabetologia* 52:614–620. DOI: 10.1007/s00125-009-  
847 1266-2.

848 Vaquero AR, Ferreira NE, Omae S V, Rodrigues M V, Teixeira SK, Krieger JE, Pereira AC.  
849 2012. Using gene-network landscape to dissect genotype effects of TCF7L2 genetic variant  
850 on diabetes and cardiovascular risk. *Physiological genomics* 44:903–14. DOI:  
851 10.1152/physiolgenomics.00030.2012.

852 Watanabe RM, Allayee H, Xiang AH, Trigo E, Hartiala J, Lawrence JM, Buchanan T a. 2007.  
853 With Gestational Diabetes Mellitus and Interacts With Adiposity to Alter Insulin Secretion  
854 in Mexican Americans. *Diabetes* 56:1481–1485. DOI: 10.2337/db06-1682.Additional.

855 Zhou Y, Oskolkov N, Shcherbina L, Ratti J, Kock KH, Su J, Martin B, Oskolkova MZ,  
856 Göransson O, Bacon J, Li W, Bucciarelli S, Cilio C, Brazma A, Thatcher B, Rung J, Wierup  
857 N, Renström E, Groop L, Hansson O. 2016. HMGB1 binds to the rs7903146 locus in  
858 TCF7L2 in human pancreatic islets. *Molecular and Cellular Endocrinology* 430:138–145.  
859 DOI: 10.1016/j.mce.2016.01.027.

860 Zhou Y, Park S, Su J, Bailey K, Ottosson-laakso E, Shcherbina L, Oskolkov N, Zhang E,  
861 Thevenin T, Bennet H, Vikman P, Wierup N, Fex M, Rung J, Wollheim C, Groop L,  
862 Hansson O, Nobrega M, Renstro E. 2014. TCF7L2 is a master regulator of insulin  
863 production and processing. *Human Molecular Genetics* 23:6419–6431. DOI:  
864 10.1093/hmg/ddu359.  
865  
866

**Table 1** (on next page)

Anthropometric and biochemical characteristics according to Body Mass Index status.

Data are presented as median and range for the most variables; P-value with Kruskal-Wallis test for quantitative variables and Chi-square test for qualitative data. BMI classification criteria: normal-weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity ( $\geq$  30.0 kg/m<sup>2</sup>). P, P-value; T2DM, Type 2 diabetes mellitus; M/F, Male/Female; BMI, Body mass index; LDL, low density lipoprotein; HDL, high density lipoprotein.

1

**Table 12**  
Anthropometric and biochemical characteristics according to Body Mass Index status.

Variable	Unit	Normal-weight	Overweight	Obesity	P
Population size	N	280	424	319	-
Gender M/F	N/N	115/165	183/241	67/252	<0.0001
Age	years old	74.3 (65.8 - 82.6)	71.6 (64.5 - 79.2)	67.9 (64.0 - 75.2)	<0.0001
BMI	kg/m <sup>2</sup>	22.8 (21.0 - 24.0)	27.3 (26.2 - 28.4)	33.1 (31.2 - 35.9)	<0.0001
Waist circumference	cm	82.0 (77.8 - 87.0)	94.0 (89.0 - 99.0)	105.0 (100.0 - 110.0)	<0.0001
Hip circumference	cm	93.0 (90.0 - 96.0)	101.0 (98.0 - 104.0)	113.0 (108.0 - 120.0)	<0.0001
Hip-waist ratio	cm/cm	0.88 (0.83 - 0.93)	0.93 (0.88 - 0.98)	0.91 (0.87 - 0.97)	<0.0001
Systolic pressure	mmHg	134.3 (121.7 - 152.0)	138.0 (127.7 - 153.0)	138.0 (125.0 - 155.0)	0.0664
Diastolic pressure	mmHg	76.2 (68.3 - 85.8)	79.7 (72.0 - 86.3)	81.0 (74.2 - 90.0)	<0.0001
Plasma glucose	mg/dL	85.0 (78.0 - 95.0)	88.0 (81.0 - 102.3)	93.0 (84.0 - 107.0)	<0.0001
Glycated hemoglobin	%	5.7 (5.5 - 6.0)	5.8 (5.6 - 6.1)	5.9 (5.6 - 6.3)	<0.0001
Total cholesterol	mg/dL	202.5 (177.0 - 234.5)	200.0 (176.0 - 228.0)	207.0 (180.0 - 230.5)	0.3732
Fasting triglyceride	mg/dL	102.5 (75.0 - 137.3)	116.5 (89.8 - 167.3)	126.0 (94.0 - 168.5)	<0.0001
LDL cholesterol	mg/dL	126.0 (104.0 - 148.0)	124.0 (104.8 - 149.0)	130.0 (106.5 - 151.0)	0.7908
HDL cholesterol	mg/dL	52.0 (42.8 - 62.0)	45.0 (38.0 - 54.0)	47.0 (41.0 - 56.0)	<0.0001
T2DM	N (%)	51 (18)	117 (28)	92 (29)	0.0048
Hypertensive	N (%)	166 (59)	279 (66)	254 (80)	<0.0001

Data are presented as median and range for the most variables; P-value with Kruskal-Wallis test for quantitative variables and Chi-square test for qualitative data.

BMI classification criteria: normal-weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity (≥ 30.0 kg/m<sup>2</sup>).

P, P-value; T2DM, Type 2 diabetes mellitus; M/F, Male/Female; BMI, Body mass index; LDL, low density lipoprotein; HDL, high density lipoprotein.

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

**Table 2** (on next page)

Association between rs7903146 TT genotype and risk for Type 2 diabetes adjusted for possible confounders.

Regression logistic analysis was adopted.

1

2

**Table 2.** Association between rs7903146 TT genotype and risk for Type 2 diabetes adjusted for possible confounders.

3

Possible confounder	<i>P</i> -value	Odds Ratio	95% Confidence Interval
Age (years old)	0.005	1.89	1.21 - 2.95
Gender (N)	0.005	1.90	1.22 - 2.97
BMI (kg/m <sup>2</sup> )	0.003	1.95	1.25 - 3.06
Waist circumference (cm)	0.004	1.93	1.23 - 3.02
Diastolic pressure (mmHg)	0.006	1.88	1.20 - 2.93
Glycated hemoglobina (%)	0.004	2.34	1.31 - 4.18
Fasting triglyceride (mg/dL)	0.005	1.90	1.22 - 2.97
HDL cholesterol (mg/dL)	0.006	1.87	1.19 - 2.92
European ancestrie (%)	0.005	1.92	1.21 - 3.05
All confounders toghether	0.006	2.35	1.28 - 4.32

Regression logistic analysis was adopted.

**Table 3**(on next page)

Association of the rs7903146 T allele with type 2 diabetes mellitus according to Body Mass Index status. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->

Volunteers without type 2 diabetes mellitus were considered as the control group. BMI classification criteria: normal-weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity ( $\geq$  30.0 kg/m<sup>2</sup>). P, P-value; 95% CI, 95% confidence interval; OR, odds ratio OR adjusted for sex and age.

1  
2  
3  
4**Table 3**

Association of the rs7903146 T allele with type 2 diabetes mellitus according to Body Mass Index status.

Volunteers without type 2 diabetes mellitus were considered as the control group.

BMI classification criteria: normal-weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity (≥ 30.0 kg/m<sup>2</sup>).

BMI Status	N	Dominant model (CC Vs CT+TT)		Recessive Model (CC+CT Vs TT)		Additive Model (CC Vs TT)		Allelic Model (C Vs T)	
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Normal-weight	280	1.23 (0.66 - 2.27)	0.512	<b>3.36 (1.46 - 7.74)</b>	<b>0.004</b>	<b>3.21 (1.31 - 7.87)</b>	<b>0.011</b>	1.52 (0.97 - 2.36)	0.066
Overweight	424	1.20 (0.78 - 1.86)	0.401	1.96 (0.99 - 3.87)	0.054	1.98 (0.96 - 4.10)	0.065	1.27 (0.92 - 1.74)	0.141
Obesity	319	1.15 (0.71 - 1.88)	0.565	1.23 (0.51 - 2.98)	0.642	1.31 (0.53 - 3.28)	0.560	1.13 (0.78 - 1.66)	0.516
Normal-weight + overweight	704	1.22 (0.86 - 1.73)	0.276	<b>2.31 (1.37 - 3.90)</b>	<b>0.002</b>	<b>2.34 (1.34 - 4.08)</b>	<b>0.003</b>	<b>1.34 (1.04 - 1.73)</b>	<b>0.025</b>
Overweight + obesity	743	1.16 (0.84 - 1.60)	0.370	1.59 (0.93 - 2.72)	0.089	1.65 (0.94 - 2.89)	0.082	1.19 (0.94 - 1.52)	0.155
Total	1023	1.16 (0.87 - 1.54)	0.305	<b>1.90 (1.22 - 2.97)</b>	<b>0.005</b>	<b>1.94 (1.21 - 3.10)</b>	<b>0.006</b>	<b>1.25 (1.01 - 1.54)</b>	<b>0.042</b>

5  
6

P, P-value; 95% CI, 95% confidence interval; OR, odds ratio OR adjusted for sex and age.

**Table 4**(on next page)

Association of the rs7903146 C allele with the Body Mass Index Status

P, P-value; 95% CI, 95% confidence interval; OR, odds ratio OR adjusted for sex and age. BMI classification criteria: normal-weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity ( $\geq 30.0$  kg/m<sup>2</sup>).

1 **Table 4**  
 2 Association of the rs7903146 C allele with the Body Mass Index Status  
 3

Control group	Case group	Dominant model (TT Vs CC+CT)		Recessive Model (TT+CT Vs CC)		Additive Model (TT Vs CC)		Allelic Model (T Vs C)	
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Normal-weight	Overweight	1.24 (0.74 - 2.09)	0.410	0.92 (0.68 - 1.26)	0.611	1.15 (0.67 - 1.98)	0.615	1.00 (0.79 - 1.26)	0.984
Normal-weight	Obesity	1.60 (0.88 - 2.92)	0.122	1.41 (1.00 - 1.98)	0.052	1.73 (0.93 - 3.21)	0.081	<b>1.34 (1.03 - 1.75)</b>	<b>0.029</b>
Normal-weight	Obesity+ overweight	1.32 (0.82 - 2.13)	0.253	1.08 (0.81 - 1.43)	0.604	1.31 (0.80 - 2.15)	0.286	1.10 (0.89 - 1.36)	0.373
Normal-weight + overweight	Obesity	1.29 (0.78 - 2.11)	0.317	<b>1.40 (1.06 - 1.84)</b>	<b>0.017</b>	1.48 (0.89 - 2.47)	0.132	<b>1.28 (1.03 - 1.58)</b>	<b>0.024</b>

4 P, P-value; 95% CI, 95% confidence interval; OR, odds ratio OR adjusted for sex and age.

5 BMI classification criteria: normal-weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>), obesity (≥ 30.0 kg/m<sup>2</sup>).

6

**Table 5** (on next page)

Association between rs7903146 CC genotype and risk for obesity adjusted for possible confounders.

Regression logistic analysis was adopted. \*Association between rs7903146 CC genotype and obesity adjusted by fasting triglyceride:  $P=0.034$ ;  $OR=1.0016$ ; 95% Confidence Interval = 1.0001 - 1.0031.

**Table 5.** Association between rs7903146 CC genotype and risk for obesity adjusted for possible confounders.

Possible confounder	<i>P</i> -value	Odds Ratio	95% Confidence Interval
Age (years old)	<0.001	0.96	0.95 - 0.98
Gender (N)	<0.001	2.85	2.08 - 3.89
Diastolic pressure (mmHg)	<0.001	1.02	1.01 - 1.03
Glycated hemoglobina (%)	0.032	1.13	1.01 - 1.27
Fasting triglyceride* (mg/dL)	0.034	1.00	1.00 - 1.00
HDL cholesterol (mg/dL)	0.443	1.00	0.99 – 1.00
All confounders together	0.017	1.41	1.06 – 1.86

Regression logistic analysis was adopted.

\*Association between rs7903146 CC genotype and obesity adjusted by fasting triglyceride:  $P=0.034$ ; OR=1.0016; 95% Confidence Interval = 1.0001 - 1.0031.

1

2

3